We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health Lifts Adjusted EPS Outlook: What's Driving It?
Read MoreHide Full Article
Key Takeaways
CVS reported a 47% jump in adjusted EPS to $1.60 on record $103B revenues, up 8% year over year.
CVS' Health Care Benefits unit swung to $314M income, led by government business and margin gains.
CVS' Pharmacy & Consumer Wellness revenues rose 12%, boosted by higher prescription volume.
CVS Health (CVS - Free Report) posted a strong third quarter, delivering a 47% year-over-year increase in adjusted earnings per share (EPS) to $1.60. Revenues reached a record $103 billion, up roughly 8% from last year, driven by revenue growth across all segments. The retail healthcare giant has raised its full-year 2025 adjusted EPS guidance for the third consecutive time, now projecting between $6.55 and $6.65 compared to the earlier range of $6.30-$6.40.
Several trends are shaping the company’s path to deliver on its targets. Health Care Benefits performance continued to be led by the government business, largely reflecting the impact of the Inflation Reduction Act on the Medicare Part D program. The division’s adjusted operating income was approximately $314 million, a significant turnaround from the operating loss recorded in the prior year quarter. The medical benefit ratio was 92.8%, a decrease of 240 basis points year over year. Further, CVS continues to make progress across all lines of Aetna business, supporting its return to target margins and regaining its industry leadership position.
The Pharmacy & Consumer Wellness segment is also expected to continue its strong momentum, closing out this year. Revenues increased nearly 12%, mainly due to pharmacy drug mix and increased prescription volume, including incremental volume resulting from CVS’ Rite Aid prescription file acquisitions. Retail pharmacy script share also grew to approximately 28.9%, reflecting the company’s emphasis on operational excellence and superior customer experiences, enabling it to benefit from pharmacy market disruption.
Updates From CVS Health’s Peers
Amazon’s (AMZN - Free Report) third-quarter 2025 net sales increased 13% to $180.2 billion, with AWS segment sales growing 20.2% year over year, its largest growth rate in 11 quarters. Operating income came in at $17.4 billion, taking into account charges related to a legal settlement with the Federal Trade Commission and severance costs for role eliminations. For the fourth quarter, Amazon expects net sales between $206.0 billion and $213.0 billion, representing 10%-13% growth compared to the fourth quarter of 2024. The outlook includes an estimated 190 basis points tailwind from foreign exchange rates.
Elevance Health (ELV - Free Report) reported third-quarter 2025 operating revenues of $50.1 billion, up 12% year over year. This was mainly driven by higher premium yields in the company’s Health Benefits segment, recently closed acquisitions and growth in Medicare Advantage membership. Elevance Health has reaffirmed its 2025 adjusted EPS of approximately $30 and continues to view $27 as the appropriate earnings baseline, excluding $3 of discrete, non-recurring items. The company is refining its pricing, accelerating digitization and automation initiatives and embedding value-based care principles across the enterprise.
CVS Stock Performance, Valuation and Estimates
In the past year, CVS Health shares have rallied 43.5% against the industry’s 5.5% fall.
Image Source: Zacks Investment Research
CVS Health is trading at a forward five-year price/sales (P/S) ratio of 0.23, lower than the industry average of 0.45.
Image Source: Zacks Investment Research
See how the analysts are projecting CVS Health’s 2025 and 2026 earnings.
Image: Bigstock
CVS Health Lifts Adjusted EPS Outlook: What's Driving It?
Key Takeaways
CVS Health (CVS - Free Report) posted a strong third quarter, delivering a 47% year-over-year increase in adjusted earnings per share (EPS) to $1.60. Revenues reached a record $103 billion, up roughly 8% from last year, driven by revenue growth across all segments. The retail healthcare giant has raised its full-year 2025 adjusted EPS guidance for the third consecutive time, now projecting between $6.55 and $6.65 compared to the earlier range of $6.30-$6.40.
Several trends are shaping the company’s path to deliver on its targets. Health Care Benefits performance continued to be led by the government business, largely reflecting the impact of the Inflation Reduction Act on the Medicare Part D program. The division’s adjusted operating income was approximately $314 million, a significant turnaround from the operating loss recorded in the prior year quarter. The medical benefit ratio was 92.8%, a decrease of 240 basis points year over year. Further, CVS continues to make progress across all lines of Aetna business, supporting its return to target margins and regaining its industry leadership position.
The Pharmacy & Consumer Wellness segment is also expected to continue its strong momentum, closing out this year. Revenues increased nearly 12%, mainly due to pharmacy drug mix and increased prescription volume, including incremental volume resulting from CVS’ Rite Aid prescription file acquisitions. Retail pharmacy script share also grew to approximately 28.9%, reflecting the company’s emphasis on operational excellence and superior customer experiences, enabling it to benefit from pharmacy market disruption.
Updates From CVS Health’s Peers
Amazon’s (AMZN - Free Report) third-quarter 2025 net sales increased 13% to $180.2 billion, with AWS segment sales growing 20.2% year over year, its largest growth rate in 11 quarters. Operating income came in at $17.4 billion, taking into account charges related to a legal settlement with the Federal Trade Commission and severance costs for role eliminations. For the fourth quarter, Amazon expects net sales between $206.0 billion and $213.0 billion, representing 10%-13% growth compared to the fourth quarter of 2024. The outlook includes an estimated 190 basis points tailwind from foreign exchange rates.
Elevance Health (ELV - Free Report) reported third-quarter 2025 operating revenues of $50.1 billion, up 12% year over year. This was mainly driven by higher premium yields in the company’s Health Benefits segment, recently closed acquisitions and growth in Medicare Advantage membership. Elevance Health has reaffirmed its 2025 adjusted EPS of approximately $30 and continues to view $27 as the appropriate earnings baseline, excluding $3 of discrete, non-recurring items. The company is refining its pricing, accelerating digitization and automation initiatives and embedding value-based care principles across the enterprise.
CVS Stock Performance, Valuation and Estimates
In the past year, CVS Health shares have rallied 43.5% against the industry’s 5.5% fall.
Image Source: Zacks Investment Research
CVS Health is trading at a forward five-year price/sales (P/S) ratio of 0.23, lower than the industry average of 0.45.
Image Source: Zacks Investment Research
See how the analysts are projecting CVS Health’s 2025 and 2026 earnings.
Image Source: Zacks Investment Research
CVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.